IP Library › Granted Patent US 11,285,221
Granted Patent B2
US 11,285,221 · App. 16/247,253 · Granted Mar 29, 2022

Treating myelomas

Inventors: Svetomir N. Markovic (Rochester, MN); Wendy K. Nevala (Rochester, MN)
Assignee: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
A61K47/6849A61K9/0019A61K9/5169A61K31/337A61K47/643
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,285,221
App. No.
16/247,253
Granted
Mar 29, 2022
Kind
B2
Abstract

This document provides methods and materials related to treating myelomas. For example, methods and materials relating to the use of a composition containing albumin-containing nanoparticle/antibody complexes (e.g., ABRAXANE®/anti-CD38 polypeptide antibody complexes) to treat myelomas are provided.

Claims (16)

1. A method for treating a mammal having myeloma, said method comprising administering to said mammal a composition comprising nanoparticle/antibody complexes containing albumin-bound paclitaxel complexed with an anti-CD38 polypeptide antibody wherein the administration of the composition increases length of progression-free survival, and wherein an average diameter of said complexes is between 0.1 and 0.9 μm.

2. The method of claim 1 , wherein said mammal is a human.

3. The method of claim 1 , wherein said myeloma is multiple myeloma.

4. The method of claim 1 , wherein the anti-CD38 antibody is Daratumumab, MOR202, SAR650984, or any combination thereof.

5. A method for treating a mammal having myeloma, wherein said method comprises administering, to said mammal, a composition comprising nanoparticle/antibody complexes comprising albumin-bound paclitaxel, wherein an average diameter of said complexes is between 0.1 and 0.9 μm, and wherein said antibody is an anti-CD38 antibody.

6. The method of claim 5 , wherein said mammal is a human.

7. The method of claim 5 , wherein said myeloma is a multiple myeloma.

8. The method of claim 5 , wherein said myeloma is a light chain myeloma.

9. The method of claim 5 , wherein said myeloma is a non-secretory myeloma.

10. The method of claim 5 , wherein the anti-CD38 antibody is Daratumumab, MOR202, SAR650984, or any combination thereof.

11. A method for treating a mammal having myeloma, wherein said method comprises administering, to said mammal, a composition comprising nanoparticle/antibody complexes comprising albumin-bound paclitaxel, wherein an average diameter of at least 50 percent of said complexes of said composition is between 0.1 and 0.9 μm, and wherein said antibodies are anti-CD38 antibodies.

12. The method of claim 11 , wherein said mammal is a human.

13. The method of claim 11 , wherein said myeloma is a multiple myeloma.

14. The method of claim 11 , wherein said myeloma is a light chain myeloma.

15. The method of claim 11 , wherein said myeloma is a non-secretory myeloma.

16. The method of claim 11 , wherein the anti-CD38 antibody is Daratumumab, MOR202, SAR650984, or any combination thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 11, 2022
From: MARKOVIC, SVETOMIR N.; NEVALA, WENDY K.
To: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
Reel/Frame 059238/0564 →
Continuity (3)
Continuation 15030568
Provisional Application 62012804 · Jun 16, 2014
Related Publication 20190216944A1 · Jul 18, 2019